Huiyun Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huiyun Pan has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Fei Xu
Department of Internal Medicine Ward, The First Affiliated Hospital of the College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
1 shared publicationHui Fang
Department of Geratology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China
1 shared publicationLihong Wang
Department of Geratology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China
1 shared publication- Senxiang Yan
Department of Radiation Oncology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication - Xia Zhang
Department of Geratology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China
1 shared publication Xuan Gao
Department of Respiratory Diseases, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, P.R. China
1 shared publication
Latest Publications
- Open Access
- 1 July 2019
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 6581-6592
Long noncoding RNA DANCR in various cancers: a meta-analysis and bioinformatics
Background: Differentiation antagonizing non-protein-coding RNA (DANCR) is a novel long noncoding RNA. Recent studies have shown that DANCR is aberrantly expressed in several types of cancer and is associated with poor outcomes. However, the clinical diagnostic significance of DANCR in tumors is not completely understood. Methods: We searched the PubMed, Medline, Web of Science, EMBASE, Cochrane Library, and Ovid databases (up to December 30, 2018) for relevant literature. A total of 11 studies with 945 cancer patients were included in the present meta-analysis. We further validated the results using The Cancer Genome Atlas (TCGA) dataset. Results: High expression of DANCR significantly predicted poor overall survival (low expression group vs high expression group; HR = 0.56, 95% CI=[0.43, 0.72], = 0.000); this was validated using TCGA. Moreover, DANCR expression was associated with advanced tumor node metastasis stage (I+II: III+IV; OR=0.22, 95% CI=[0.14, 0.35], P=0.001) and lymph node metastasis (no:yes; OR=0.21, 95% CI=[0.13, 0.35], P=0.001). Conclusion: Our results suggest that elevated DANCR is related to poor clinical outcomes and could serve as a potential prognostic biomarker of cancer.
- 1 July 2019
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 6581-6592
Open AccessLong noncoding RNA DANCR in various cancers: a meta-analysis and bioinformatics
Background: Differentiation antagonizing non-protein-coding RNA (DANCR) is a novel long noncoding RNA. Recent studies have shown that DANCR is aberrantly expressed in several types of cancer and is associated with poor outcomes. However, the clinical diagnostic significance of DANCR in tumors is not completely understood. Methods: We searched the PubMed, Medline, Web of Science, EMBASE, Cochrane Library, and Ovid databases (up to December 30, 2018) for relevant literature. A total of 11 studies with 945 cancer patients were included in the present meta-analysis. We further validated the results using The Cancer Genome Atlas (TCGA) dataset. Results: High expression of DANCR significantly predicted poor overall survival (low expression group vs high expression group; HR = 0.56, 95% CI=[0.43, 0.72], = 0.000); this was validated using TCGA. Moreover, DANCR expression was associated with advanced tumor node metastasis stage (I+II: III+IV; OR=0.22, 95% CI=[0.14, 0.35], P=0.001) and lymph node metastasis (no:yes; OR=0.21, 95% CI=[0.13, 0.35], P=0.001). Conclusion: Our results suggest that elevated DANCR is related to poor clinical outcomes and could serve as a potential prognostic biomarker of cancer.
- Open Access
- 2 October 2018
- Published by Spandidos Publications in Oncology Reports
- Vol. 40 (6) , 3458-3468
Pectolinarigenin inhibits non‑small cell lung cancer progression by regulating the PTEN/PI3K/AKT signaling pathway
Lung cancer is the principal cause of cancer‑-associated mortality. Pectolinarigenin (Pec) reportedly has effective antitumor activity against certain cancer types. Phosphatase and tensin homolog (PTEN) is a well‑known tumor suppressor and serves a vital role in cancer progression. However, the effect of Pec on non‑small cell lung cancer (NSCLC) cell proliferation and metastasis, and the underlying mechanism, has not yet been elucidated. In the present study, it was demonstrated that Pec inhibited the proliferation of A549 and Calu‑3 cells in dose‑ and time‑dependent manners. The apoptosis rate significantly increased with increasing doses of Pec. Apoptosis‑associated protein expression was additionally altered by Pec exposure. Pec was able to suppress the metastasis of NSCLC cells; it upregulated the mRNA and protein expression levels of E‑cadherin, and downregulated the mRNA and protein expression levels of vimentin. Additionally, Pec was able to activate PTEN and subsequently downregulate the PI3K/protein kinase B (AKT) signaling pathway. In summary, Pec was able to inhibit cell proliferation, promote apoptosis and suppress metastasis in NSCLC cells through the PTEN/PI3K/AKT signaling pathway, indicating that Pec is a potential agent for NSCLC therapy.
- 2 October 2018
- Published by Spandidos Publications in Oncology Reports
- Vol. 40 (6) , 3458-3468
Open AccessPectolinarigenin inhibits non‑small cell lung cancer progression by regulating the PTEN/PI3K/AKT signaling pathway
Lung cancer is the principal cause of cancer‑-associated mortality. Pectolinarigenin (Pec) reportedly has effective antitumor activity against certain cancer types. Phosphatase and tensin homolog (PTEN) is a well‑known tumor suppressor and serves a vital role in cancer progression. However, the effect of Pec on non‑small cell lung cancer (NSCLC) cell proliferation and metastasis, and the underlying mechanism, has not yet been elucidated. In the present study, it was demonstrated that Pec inhibited the proliferation of A549 and Calu‑3 cells in dose‑ and time‑dependent manners. The apoptosis rate significantly increased with increasing doses of Pec. Apoptosis‑associated protein expression was additionally altered by Pec exposure. Pec was able to suppress the metastasis of NSCLC cells; it upregulated the mRNA and protein expression levels of E‑cadherin, and downregulated the mRNA and protein expression levels of vimentin. Additionally, Pec was able to activate PTEN and subsequently downregulate the PI3K/protein kinase B (AKT) signaling pathway. In summary, Pec was able to inhibit cell proliferation, promote apoptosis and suppress metastasis in NSCLC cells through the PTEN/PI3K/AKT signaling pathway, indicating that Pec is a potential agent for NSCLC therapy.